Peking University People's Hospital is conducting a phase two, randomized, open-label, multicenter study to compare the efficacy and safety of using high-dose dexamethasone in combination with Tacrolimus, an immunosuppressive, compared to using high-dose dexamethasone alone as a first line therapy for adults with newly diagnosed primary ITP. Eligibility includes adults over the age of 18 years who have a platelet count under 30,000 µL or under 50,000 µL with bleeding symptoms. There are a range of exclusion that can be accessed through the below study link.
China
https://www.clinicaltrials.gov/ct2/show/NCT04747080?recrs=a&cond=Immune+Thrombocytopenia&draw=2&rank=27
Status Unknown